Table 2. Directional differentiation to neuroectodermal or mesendodermal cell lineages.
| Conditions | Pluri. | Mesendo. | Neuroecto. | ||||||
| Activin | FGF | BMP | Nanog | Oct4 | T | Sox2 | Pax6 | Sox1 | |
| 1 | - | - | - | - | - | - | ++ | ± | - |
| 2 | - | PD 1 | - | - | - | - | + | ++ | ± |
| 3 | - | - | DM 1 | - | - | ± | ++ | ± | ++ |
| 4 | - | PD 1 | DM 1 | - | - | ± | ++ | + | + |
| 5 | SB 10 | - | - | - | - | - | ++ | ± | + |
| 6 | SB 10 | PD 1 | - | - | - | - | + | ++ | + |
| 7 | SB 10 | - | DM 1 | - | - | - | ++ | ± | ++ |
| 8 | SB 10 | PD 1 | DM 1 | - | - | - | ++ | + | ++ |
| 9 | Act 10 | - | - | + | ++ | + | ++ | - | - |
| 10 | Act 10 | PD 1 | - | ++ | ++ | - | ++ | - | - |
| 11 | Act 10 | - | DM 1 | + | ++ | ++ | + | - | - |
| 12 | Act 10 | PD 1 | DM 1 | + | + | - | + | - | - |
| 13 | Act 10 | FGF 15 | - | ++ | ++ | + | ++ | - | - |
| 14 | Act 10 | FGF 15 | DM 1 | ++ | ++ | + | ++ | - | - |
| 15 | Act 10 | FGF 15 | BMP 10 | + | ++ | + | + | - | - |
CMK6SFF cells were treated in the MT-CDM medium in the presence or absence of 10 µM SB, 1 µM PD, 1 µM DM, and 10 ng/ml activin for 4 days. SB, SB431542 (TGFβ inhibitor). PD, PD0325901 (MEK inhibitor). DM, dorsomorphin (BMP inhibitor). Act, activin. Pluri, pluripotency marker. Mesendo, mesendoderm marker. Neuroecto, neuroectoderm marker.